トレプロスチニルナトリウム薬品の考察と市場予測（2032年）

当レポートでは、トレプロスチニルナトリウム薬品の主要6市場（米国・ドイツ・フランス・イタリア・スペイン・英国）について調査分析し、作用機序、用法と用量、研究開発活動についての考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 肺動脈性肺高血圧症におけるトレプロスチニルナトリウムの概要

• 製品の詳細
• 臨床開発
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新しい治療法）

第5章 トレプロスチニルナトリウム市場の評価

• 肺動脈性肺高血圧症におけるトレプロスチニルナトリウムの市場の見通し
• 主要6市場の分析
  • 主要6市場の肺動脈性肺高血圧症向けトレプロスチニルナトリウムの市場規模
• 市場の分析：国別
  • 米国の肺動脈性肺高血圧症向けトレプロスチニルナトリウムの市場規模
  • ドイツの肺動脈性肺高血圧症向けトレプロスチニルナトリウムの市場規模
  • 英国の肺動脈性肺高血圧症向けトレプロスチニルナトリウムの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Treprostinil sodium, Clinical Trial Description, 2022
• Table 2: Treprostinil sodium : General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5:Treprostinil sodium Market Size in the 6MM, in USD million (2019-2032)
• Table 6:Treprostinil sodium Market Size in the United States, in USD million (2019-2032)
• Table 7:Treprostinil sodium Market Size in Germany, in USD million (2019-2032)
• Table 8:Treprostinil sodium Market Size in France, in USD million (2019-2032)
• Table 9:Treprostinil sodium Market Size in Italy, in USD million (2019-2032)
• Table 10:Treprostinil sodium Market Size in Spain, in USD million (2019-2032)
• Table 11:Treprostinil sodium Market Size in the United Kingdom, in USD million (2019-2032)

List of Figures

• Figure 1: Market Size of Treprostinil sodium in the 6MM, in USD million (2019-2032)
• Figure 2: Market Size of Treprostinil sodium in the United States, in USD million (2019-2032)
• Figure 3: Market Size of Treprostinil sodium in Germany, in USD million (2019-2032)
• Figure 4: Market Size of Treprostinil sodium in France, in USD million (2019-2032)
• Figure 5: Market Size of Treprostinil sodium in Italy, in USD million (2019-2032)
• Figure 6: Market Size of Treprostinil sodium in Spain, in USD million (2019-2032)
• Figure 7: Market Size of Treprostinil sodium in the United Kingdom, in USD million (2019-2032)

"Treprostinil sodium Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Treprostinil sodium for Pulmonary Arterial Hypertension in the 6MM. A detailed picture of the Treprostinil sodium for Pulmonary Arterial Hypertension in the 6MM, i.e., United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom), for the study period 2019-2032 is provided in this report along with a detailed description of the Treprostinil sodium for Pulmonary Arterial Hypertension. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Treprostinil sodium market forecast, analysis for Pulmonary Arterial Hypertension in the 6MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Pulmonary Arterial Hypertension.

Drug Summary:

Treprostinil is a tricyclic benzindene analog of prostacyclin with similar antiplatelet and vasodilatory actions. Treprostinil is chemically stable in either sterile water or 0.9% sodium chloride and 5% dextrose solutions at room temperature. These characteristics and the relatively long half-life, in the range of 2-4 h, make this drug suitable for SC infusion.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Treprostinil sodium description, mechanism of action, dosage and administration, research and development activities in Pulmonary Arterial Hypertension.
• Elaborated details on Treprostinil sodium regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Treprostinil sodium research and development activity in Pulmonary Arterial Hypertension details across the United States, and Europe.
• The report also covers the patents information with expiry timeline around Treprostinil sodium.
• The report contains forecasted sales of Treprostinil sodium for Pulmonary Arterial Hypertension till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Pulmonary Arterial Hypertension.
• The report also features the SWOT analysis with analyst views for Treprostinil sodium in Pulmonary Arterial Hypertension.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Treprostinil sodium Analytical Perspective by DelveInsight

• In-depth Treprostinil sodium Market Assessment

This report provides a detailed market assessment of Treprostinil sodium in Pulmonary Arterial Hypertension in the 6MM, i.e., United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom). This segment of the report provides forecasted sales data from 2022 to 2032.

• Treprostinil sodium Clinical Assessment

The report provides the clinical trials information of Treprostinil sodium for Pulmonary Arterial Hypertension covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Pulmonary Arterial Hypertension is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Treprostinil sodium dominance.
• Other emerging products for Pulmonary Arterial Hypertension are expected to give tough market competition to Treprostinil sodium and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Treprostinil sodium in Pulmonary Arterial Hypertension.
• Our in-depth analysis of the forecasted sales data of Treprostinil sodium from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Treprostinil sodium in Pulmonary Arterial Hypertension.

Key Questions

• What is the product type, route of administration and mechanism of action of Treprostinil sodium?
• What is the clinical trial status of the study related to Treprostinil sodium in Pulmonary Arterial Hypertension and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Treprostinil sodium development?
• What are the key designations that have been granted to Treprostinil sodium for Pulmonary Arterial Hypertension?
• What is the forecasted market scenario of Treprostinil sodium for Pulmonary Arterial Hypertension?
• What are the forecasted sales of Treprostinil sodium in the 6MM, including the United States, and Europe (Germany, France, Italy, Spain, and the United Kingdom)?
• What are the other emerging products available in Pulmonary Arterial Hypertension and how are they giving competition to Treprostinil sodium for Pulmonary Arterial Hypertension?
• Which are the late-stage emerging therapies under development for the treatment of Pulmonary Arterial Hypertension?

Table of Contents

1. Report Introduction

2. Treprostinil sodium Overview in Pulmonary Arterial Hypertension

• 2.1 Product Detail
• 2.2 Clinical Development
  • 2.2.1 Safety and Efficacy
• 2.3 Regulatory milestones
• 2.4 Other Development Activities
• 2.5 Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)*

5. Treprostinil sodium Market Assessment

• 5.1 Market Outlook of Treprostinil sodium in Pulmonary Arterial Hypertension
• 5.2 6MM Market Analysis
  • 5.2.1 Market Size of Treprostinil sodium in the 6MM for Pulmonary Arterial Hypertension
• 5.3 Country-wise Market Analysis
  • 5.3.1 Market Size of Treprostinil sodium in the United States for Pulmonary Arterial Hypertension
  • 5.3.2 Market Size of Treprostinil sodium in Germany for Pulmonary Arterial Hypertension
  • 5.3.3 Market Size of Treprostinil sodium in France for Pulmonary Arterial Hypertension
  • 5.3.4 Market Size of Treprostinil sodium in Italy for Pulmonary Arterial Hypertension
  • 5.3.5 Market Size of Treprostinil sodium in Spain for Pulmonary Arterial Hypertension
  • 5.3.6 Market Size of Treprostinil sodium in the United Kingdom for Pulmonary Arterial Hypertension

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1 Bibliography
• 8.2 Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Option